Search research articles

Search research articles

Related Experiment Videos

[HIV infection and comorbidities].

Karine Lacombe¹, Jérôme Pacanowski

¹Service de maladies infectieuses, hôpital Saint-Antoine, 75571 Paris Cedex 12. karine.lacombe@sat.aphp.fr

La Revue Du Praticien

|June 17, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effectiveness and Safety of Lenacapavir-Containing Regimens in Highly Experienced HIV-Infected Patients With Multidrug Resistance: Real-world Results From the French Compassionate Use Program <sup>a</sup>.

Open forum infectious diseases·2026

Same author

Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial.

The lancet. HIV·2026

Same author

Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series.

Antiviral therapy·2026

Same author

Factors associated with loss to follow-up among people living with HIV in France.

AIDS (London, England)·2026

Same author

Acute Hepatitis B among PWH Switched to Long-Acting Cabotegravir/Rilpivirine: The Context Matters.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Severe hyperglycemia after initiation of long-acting cabotegravir in two antiretroviral treatment-controlled people with HIV.

Diabetes & metabolism·2026

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Highly Active Antiretroviral Therapy (HAART) has reduced HIV mortality, but non-HIV causes like cancer and hepatitis C are now leading deaths. Increased life expectancy necessitates proactive screening for hepatitis B and C in HIV patients.

Area of Science:

Infectious Diseases
Hepatology
Oncology
Cardiology
Public Health

Context:

Highly Active Antiretroviral Therapy (HAART) has significantly improved outcomes for individuals with Human Immunodeficiency Virus (HIV).
Despite HAART, opportunistic infections remain a concern, but non-HIV related conditions are emerging as primary causes of mortality.
Increased lifespan in HIV patients treated with HAART leads to a higher prevalence of chronic conditions.

Purpose:

To analyze mortality causes in the HIV-infected population in France.
To identify the main non-HIV related causes of death in patients on HAART.
To highlight the impact of chronic hepatitis B and C on the longevity and management of HIV patients.

Summary:

Related Experiment Videos

The "Mortalité 2000" study revealed that while opportunistic infections decreased, they still caused 47% of deaths in HIV patients.
Cancer, chronic hepatitis C, cardiovascular diseases, and suicide constitute the primary non-HIV related causes of death, accounting for 50% of mortality.
The study underscores the increased frequency of chronic viral hepatitis B and C complications due to longer life expectancy with HAART.

Impact:

Recommends systematic screening for Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) markers in all HIV-infected patients.
Advocates for modified clinical and therapeutic management strategies for HIV/HCV and HIV/HBV co-infected patients.
Emphasizes the need to address non-communicable diseases and co-infections to further improve survival and quality of life in the HIV-infected population.